10 completed, 7 recruiting, 4 unknown, 2 terminated. 26 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 10, Recruiting 7, Unknown 4, Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 5 | Completed 3, Recruiting 2 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Leflunomide: new trials by email Literature Review of Leflunomide trials Research Report on Leflunomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes Leflunomide 10mg, Leflunomide 20mg, Decitabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | West Virginia University | 26 | 2025-07-15 | 2026-04-23 |
| Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients Leflunomide 20 mg - Hematologic Malignancies | Phase 2 | Recruiting | Tata Memorial Centre | 22 | 2024-10-18 | 2026-07-16 |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant Leflunomide tablet - Musculoskeletal Disease Other, GVHD, Chronic | Phase 2 | Terminated | Tata Memorial Centre | 1 | 2023-09-18 | 2025-09-10 |
| Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children Leflunomide, Steroid Drug - Idiopathic Pulmonary Hemosiderosis, Leflunomide | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 34 | 2023-06-01 | 2023-07-10 |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Cholestyramine, Leflunomide - Smoldering Plasma Cell Myeloma | Phase 2 | Active not recruiting | City of Hope Medical Center | 27 | 2022-03-07 | 2026-04-30 |
| New Clinical End-points in Patients With Primary Sjögren's Syndrome Hydroxychloroquine 400mg/d, Leflunomide 20mg/d, Mycophenolate mofetil 2000mg/d - Primary Sjögren's Syndrome (pSS) | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2022-01-20 | 2024-11-01 |
| Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders Leflunomide - Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder | Phase 2 | Completed | City of Hope Medical Center | 1 | 2021-05-05 | 2023-12-05 |
| Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Best Practice, Leflunomide, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 2 | 2021-01-07 | 2024-07-03 |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma Dexamethasone, Leflunomide, Pomalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Recruiting | City of Hope Medical Center | 29 | 2020-11-24 | 2026-05-29 |
| Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor Leflunomide Pill - Neuroendocrine Tumors | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 50 | 2020-07-01 | 2024-08-07 |
| Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma Leflunomide, Quality-of-Life Assessment, Questionnaire Administration - Smoldering Plasma Cell Myeloma | Phase 2 | Withdrawn | City of Hope Medical Center | 2019-12-11 | 2019-11-14 | |
| Leflunomide in Previously Treated Metastatic Triple Negative Cancers Leflunomide - Breast Neoplasms, Breast Diseases | Phase 1 / Phase 2 | Completed | Joseph Sparano | 17 | 2019-04-16 | 2026-03-19 |
| Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 12 | 2015-12-02 | 2023-10-10 |
| The Research of Standard Diagnosis and Treatment for HSPN in Children Prednisone, Cyclophosphamide(CTX), Mycophenolate mofetil(MMF) - Henoch-Schoenlein Purpura Nephritis | Phase 2 | Unknown | Nanjing Children's Hospital | 100 | 2015-08-01 | 2020-02-26 |
| An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria Leflunomide and orotic acid - Viruria, Viremia | Phase 2 | Terminated | Changzheng-Cinkate | 24 | 2012-07-01 | 2018-12-05 |
| A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis MLTA3698A, adalimumab, leflunomide - Rheumatoid Arthritis | Phase 2 | Completed | Genentech, Inc. | 211 | 2010-11-01 | 2016-11-02 |
| Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid leflunomide - Bullous Pemphigoid | Phase 2 | Unknown | University Hospital, Limoges | 54 | 2007-09-01 | 2008-12-04 |
Showing 20 of 26. Sign in to see all of them.
Arthritis, Rheumatoid (3) · Hematologic Neoplasms (2) · Inflammation (2) · Lupus Erythematosus, Systemic (2) · Multiple Myeloma (2) · Smoldering Multiple Myeloma (2) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Astrocytoma (1) · Autoimmune Diseases (1) · Brain Neoplasms (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Central Nervous System Neoplasms (1)
City of Hope Medical Center (6) · Pfizer (2) · Tata Memorial Centre (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Changzheng-Cinkate (1) · Genentech, Inc. (1) · Joseph Sparano (1) · N.N. Petrov National Medical Research Center of Oncology (1) · NYU Langone Health (1) · Nanjing Children's Hospital (1) · National Eye Institute (NEI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sanofi (1)
United States (15) · China (3) · France (2) · India (2) · Bulgaria (1) · Canada (1) · Chile (1) · Egypt (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Mexico (1) · Peru (1) · Poland (1) · Romania (1)
Michael A Rosenzweig (2) · Michael Rosenzweig (2) · Aihua Zhang, M.D. (1) · Alison L. Hannah, MBBS (1) · Ann Traynor, MD (1) · Betty Diamond, MD (1) · Bevra Hahn, MD (1) · Christiane Querfeld (1) · Dan C Nordstrom, MD, PhD (1) · Evgeny Imyanitov (1) · Hong Zhao (1) · Iris Chan (1) · James W Williams, MD (1) · John C. Davis, Jr., M.D., M.P.H. (1)
PMID 10515382, PMID 10573044, PMID 12659416, PMID 15528753, PMID 15845896, PMID 18307672, PMID 19955306, PMID 20837781, PMID 22093814, PMID 22859346, PMID 23146063, PMID 25359150, PMID 25790744, PMID 25949314, PMID 27047808, PMID 27418009, PMID 27682069, PMID 28544502, PMID 28986189, PMID 29190347, PMID 29211658, PMID 31054984, PMID 31153807, PMID 32017805, PMID 32202631, PMID 32268821, PMID 34305463, PMID 35169281, PMID 36853224
P30CA033572 (3), 2005 (1)